nexo – Nexo Therapeutics

Calico and Nexo Enter into Collaboration to Discover and Develop Small Molecule Therapies for Age-Related Diseases

Posted on 21 de May de 2026 (21 de May de 2026)

SOUTH SAN FRANCISCO, Calif. and WATERTOWN, Mass., May 21, 2026 — Calico Life Sciences LLC (Calico), a clinical-stage biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, Ph.D., and Nexo Therapeutics Inc. (Nexo), today announced a multi-target collaboration to discover and develop small molecule therapeutics for challenging […]

BioWorld: Nexo emerges with $60M series A, takes aim at ‘elusive’ targets

Posted on 4 de August de 2023 (21 de May de 2026)

BioWorld covered Nexo’s emergence from stealth, its $60 million financing and the company’s ambition to translate chemistry and chemical biology into programs against elusive cancer targets. […]

MedCity News: Bio Startup Nexo Lands $60M to Climb to New Heights in Cancer Drug R&D

Posted on 27 de July de 2023

MedCity News covered Nexo’s launch, financing and research alliance with MD Anderson, emphasizing the company’s strategy to broaden the amino acids addressable by covalent chemistry. […]

Pharmaceutical Technology: Oncology company Nexo Therapeutics raises $60m in Series A round

Posted on 27 de July de 2023

Pharmaceutical Technology reported on Nexo’s Series A financing and described how the company’s platform combines covalent ligand discovery and chemical biology to pursue previously difficult oncology targets. […]

C&EN: Nexo launches with oncology drug discovery program

Posted on 27 de July de 2023

C&EN highlighted Nexo’s $60 million Series A financing and its effort to apply covalent chemistry to cancer targets that have been difficult to drug with conventional approaches. […]

BioPharma Dive: Nexo allies with MD Anderson in pursuit of covalent cancer drugs

Posted on 26 de July de 2023

BioPharma Dive reported on Nexo’s financing and five-year MD Anderson partnership, framing the company as part of a new wave of startups bringing a more deliberate approach to covalent drug design. […]

Nexo Therapeutics Launches With $60 Million Series A Financing

Posted on 26 de July de 2023 (21 de May de 2026)

Nexo Therapeutics launched with $60 million in Series A funding led by Versant Ventures and outlined a platform designed to discover covalent drugs against previously intractable cancer targets. […]

MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets

Posted on 26 de July de 2023 (21 de May de 2026)

MD Anderson and Nexo Therapeutics announced a multi-year collaboration that combines Nexo’s discovery platform with MD Anderson’s TRACTION capabilities to move new small-molecule cancer therapies toward the clinic. […]

Author: nexo

Posts by nexo

Calico and Nexo Enter into Collaboration to Discover and Develop Small Molecule Therapies for Age-Related Diseases

BioWorld: Nexo emerges with $60M series A, takes aim at ‘elusive’ targets

MedCity News: Bio Startup Nexo Lands $60M to Climb to New Heights in Cancer Drug R&D

Pharmaceutical Technology: Oncology company Nexo Therapeutics raises $60m in Series A round

C&EN: Nexo launches with oncology drug discovery program

BioPharma Dive: Nexo allies with MD Anderson in pursuit of covalent cancer drugs

Nexo Therapeutics Launches With $60 Million Series A Financing

MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets